Literature DB >> 17083072

Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart.

Walmor C De Mello1.   

Abstract

INTRODUCTION: The effect of chronic administration of eplerenone on cardiac remodelling and electrical properties was investigated in the failing heart of cardiomyopathic hamsters (TO-2) at five months of age.
MATERIALS AND METHODS: Two-month-old hamsters were treated with eplerenone (200 mg/kg/day) administered into the chow for a period of three months. Measurements of membrane potential were performed with intracellular microelectrodes connected to a high impedance DC amplifier. The thickness of the ventricular wall as well as the area of fibrosis were measured. To investigate the influence of eplerenone on the electrogenic sodium pump myocytes were isolated from the ventricle and the pump current density was measured in voltage clamped cells using the whole cell clamp configuration.
RESULTS: The results indicated that: 1) the width of the left and right ventricular wall was significantly reduced; 2) the heart weight/body weight ratio was decreased by 38+/-2.4% (n=24) (p<0.05); 3) the fibrotic area in the left ventricle (LV) was reduced by 12.6+/-2% (n=25) (p<0.05); 4) the incidence of cardiac arrhythmias was decreased from 58+/-3.8% (n=20) in the control to 40+/-4.1% (n=20) (p<0.05) in animals treated with eplerenone. Moreover, a significant reduction in the dispersion of the QT interval was found with the drug; 5) eplerenone increased the resting potential of ventricular fibres from 64.3+/-1.5 mV to 73.4+/-1.4 mV (n=30) (p<0.05), an effect related to the activation of an electrogenic sodium pump. The conduction velocity, in longitudinal direction, was enhanced from 50+/-2.2 cm/s (n=10) in the controls to 59+/-2.4 cm/s (n=13) (p<0.05) in animals treated with eplerenone.
CONCLUSIONS: Eplerenone reduces cardiac remodelling, the incidence of cardiac arrhythmias and improves impulse propagation, an effect in part related to the antifibrotic effect of the drug but also to the activation of the electrogenic sodium pump.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083072     DOI: 10.3317/jraas.2006.005

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  11 in total

Review 1.  Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

2.  Cardiac fibrosis as a determinant of ventricular tachyarrhythmias.

Authors:  Norishige Morita; William J Mandel; Yoshinori Kobayashi; Hrayr S Karagueuzian
Journal:  J Arrhythm       Date:  2014-12-01

3.  Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy?

Authors:  Hrayr S Karagueuzian
Journal:  Am J Cardiovasc Dis       Date:  2011-06-12

4.  Differences in distribution of fibrosis in the ventricles underlie dominant arrhythmia vulnerability of the right ventricle in senescent mice.

Authors:  M Noorman; H V M van Rijen; T A B van Veen; J M T de Bakker; M Stein
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

5.  Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.

Authors:  Walmor C De Mello; Yamil Gerena
Journal:  Regul Pept       Date:  2008-06-08

Review 6.  Should aldosterone blockade be used beyond current indications in heart failure?

Authors:  Marcelle D Smit; Isabelle C van Gelder; Michael Böhm; Hans-Ruprecht Neuberger; Dirk J van Veldhuisen
Journal:  Curr Heart Fail Rep       Date:  2009-06

7.  Effect of spironolactone on ventricular arrhythmias in patients with left ventricular systolic dysfunction and implantable cardioverter defibrillators.

Authors:  Abdul Wase; Naga Garikipati; Omar Mufti; Zulfiqar Mirza; Aparna Innaparthy; Anwarul Kabir; Mohammed B Quraishi; Ronald Markert
Journal:  Indian Heart J       Date:  2012-04-28

8.  Eplerenone repolarizes muscle membrane through Na,K-ATPase activation by Tyr10 dephosphorylation.

Authors:  Simon Breitenbach; Frank Lehmann-Horn; Karin Jurkat-Rott
Journal:  Acta Myol       Date:  2016-10

Review 9.  What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries.

Authors:  Robert Sykes; Daniel Doherty; Kenneth Mangion; Andrew Morrow; Colin Berry
Journal:  Interv Cardiol       Date:  2021-06-10

10.  RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.

Authors:  Ibrahim F Benter; Fawzi Babiker; Ibrahim Al-Rashdan; Mariam Yousif; Saghir Akhtar
Journal:  J Diabetes Res       Date:  2013-08-27       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.